DOCSLIB.ORG

Randomised Controlled Trial of the Use of Three Dressing Preparations in the Management of Chronic Ulceration of the Foot in Diabetes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Health Technology Assessment 2009; Vol. 13: No. 54 Randomised controlled trial of the use of three dressing preparations in the management of chronic ulceration of the foot in diabetes WJ Jeffcoate, PE Price, CJ Phillips, FL Game, E Mudge, S Davies, CM Amery, ME Edmonds, OM Gibby, AB Johnson, GR Jones, E Masson, JE Patmore, D Price, G Rayman and KG Harding November 2009 DOI: 10.3310/hta13540 Health Technology Assessment NIHR HTA programme www.hta.ac.uk HTA How to obtain copies of this and other HTA programme reports An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable CD-ROM is also available (see below). Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our Despatch Agents. Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph. You can order HTA monographs from our Despatch Agents: – fax (with credit card or official purchase order) – post (with credit card or official purchase order or cheque) – phone during office hours (credit card only). Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. Contact details are as follows: HTA Despatch Email: [email protected] Magellan Tel: 02392 492 000 Concept House, Bell Road Fax: 02392 478 555 Basingstoke, Hants RG24 8FB, UK Fax from outside the UK: +44 2392 478 555 NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30–40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume. Payment methods Paying by cheque If you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit card The following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase order You can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD? Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide. The website also provides information about the HTA programme and lists the membership of the various committees. Abstract ............................................................ iii Contents ............................................................Progress.of.the.study. .................................... v . 51 Contribution.of.authors.and.collaborators. .. 51 Randomised controlled trial of the use List of abbreviationsTrial.Steering ...........................................Committee. ............................ vii . 51 Data.Monitoring.and.Ethics.Committee. .... 51 of three dressing preparations in the Executive summary ........................................... ix References ......................................................... 53 management of chronic ulceration of the Chapter 1 BackgroundAppendix ................................................1 . 1 foot in diabetes IntroductionIndications. ................................................ for taking other medications. 1 during the course Evidenceof. basethe study.for.effectiveness ..................................................of.management.strategies. 55 1 IssuesAppendix.surrounding 2 .the.choice.of.outcome.measures. .. 2 1* 2 3 Cost-effectivenessAll other medications. ........................................ taken during the. 2 course of the study . WJ Jeffcoate, PE Price, CJ Phillips, Objectives................................................................... .................................................... 2 59 FL Game,1 E Mudge,2 S Davies,3 CM Amery,4 ChapterAppendix 2 3 ME Edmonds,5 OM Gibby,6 AB Johnson,7 Study designMethods and of methods off-loading ......................... by dressing allocation. 5 69 Design. ......................................................... 5 GR Jones,8 E Masson,9 JE Patmore,9 D Price,10 RandomisationAppendix 4 . ............................................ 5 11 2 Setting.Reasons......................................................... for withdrawal by dressing .allocation5 73 G Rayman and KG Harding Target.population. ....................................... 5 InclusionAppendix.criteria 5 . ......................................... 5 1Nottingham University Hospitals Trust, Nottingham, UK ExclusionSerious.criteria adverse. ........................................ events ................................ 5 . 75 2Department of Wound Healing, School of Medicine, Cardiff University, UK Baseline.assessment. .................................... 6 3Institute of Health Research, Swansea University, UK Appendix 6 Clinical.care. ................................................ 6 4Leeds General Infirmary, Leeds, UK WithdrawalChanges. .................................................. in cross-sectional area of the. ulcers7 between 5 End.pointsbaseline. .................................................. and visits . 7 Kings College Hospital, London, UK Economic7 (12.evaluation weeks) and. .................................. 13 (24 weeks) .................. 7 . 79 6Royal Gwent Hospital, Newport, UK Sample.size. ................................................. 9 7Southmead Hospital, Bristol, UK DataAppendix.management 7 . ...................................... 9 8East Lancashire Hospitals NHS Trust, Blackburn, UK DeviationsBaseline.from .demographicsthe.planned.protocol by outcome. ....... .status9 85 9Hull Royal Infirmary, Hull, UK 10Singleton and Morriston Hospitals, Swansea, UK ChapterHealth 3 Technology Assessment reports published to date . 11 Results.................................................................. ........................................................ 11 87 Ipswich Hospital, Ipswich, UK Recruitment,.retention.and.primary.outcome 11 DemographicsHealth Technology.of.participants Assessment. .................... 11 *Corresponding author Total.medicationsprogramme.prescribed .................................................. ...................... 13 .107 Ulcer.characteristics.at.baseline. ................. 13 Declared competing interests of authors: none Methods.of.off-loading.used.at.visit.1. ........ 16 Primary.outcome.–.incidence.of.healing. .... 16 Secondary.outcomes.–.. Published November 2009 ulcer-related.outcomes. ........................... 23 Secondary.outcomes.–.patient-related.outcomes 28 DOI: 10.3310/hta13540 Secondary.outcomes.–.process-related.outcomes 31 Health.economic.analysis. ........................... 32 This report should be referenced as follows: Data.not.presented. ..................................... 43 Jeffcoate WJ, Price PE, Phillips CJ, Game FL, Mudge E, Davies S, et al. Randomised controlled trial of Chapter 4 the use of three dressing preparations in the management of chronic ulceration of the foot in diabetes. Discussion ................................................... 45 Health Technol Assess 2009;13(54). Cost-effectiveness.analysis. .......................... 47 Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta Medica/ Chapter 5 EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/Clinical Medicine. Conclusions ................................................. 49 Acknowledgements .......................................... 51 Participating.centres. ................................... 51 NIHR Health Technology Assessment programme he.Health.Technology.Assessment.(HTA).programme,.part.of.the.National.Institute.for.Health. TResearch.(NIHR),.was.set.up.in.1993..It.produces.high-quality.research.information.on.the. effectiveness,.costs.and.broader.impact.of.health.technologies.for.those.who.use,.manage.and.provide.care. in.the.NHS..‘Health.technologies’.are.broadly.defined.as.all.interventions.used.to.promote.health,.prevent. and.treat.disease,.and.improve.rehabilitation.and.long-term.care. The.research.findings.from.the.HTA.programme.directly.influence.decision-making.bodies.such.as.the. National.Institute.for.Health.and.Clinical.Excellence.(NICE).and.the.National.Screening.Committee. (NSC)..HTA.findings.also.help.to.improve.the.quality.of.clinical.practice.in.the.NHS.indirectly.in.that.they. form.a.key.component.of.the.‘National.Knowledge.Service’. The.HTA.programme.is.needs.led.in.that.it.fills.gaps.in.the.evidence.needed.by.the.NHS..There.are.three. routes.to.the.start.of.projects. First.is.the.commissioned.route..Suggestions.for.research.are.actively.sought.from.people.working.in.the. NHS,.from.the.public.and.consumer.groups.and.from.professional.bodies.such.as.royal.colleges.and.NHS. trusts..These.suggestions.are.carefully.prioritised.by.panels.of.independent.experts.(including.NHS.service. users)..The.HTA.programme.then.commissions.the.research.by.competitive.tender. Second,.the.HTA.programme.provides.grants.for.clinical.trials.for.researchers.who.identify.research.
Recommended publications
  • UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C

    UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* GENOCEA BIOSCIENCES, INC. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 372427 10 4 (CUSIP Number) Victoria A. Whyte GlaxoSmithKline plc 980 Great West Road Brentford, Middlesex TW8 9GS England Telephone: +44 (0)208 047 5000 Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) July 30, 2015 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐ Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
  • Corporate Governance

    Corporate Governance

    Strategic report Governance and remuneration Financial statements Investor information Corporate Governance In this section Chairman’s Governance statement 78 The Board 80 Corporate Executive Team 83 Board architecture 85 Board roles and responsibilities 86 Board activity and principal decisions 87 Our purpose, values and culture 90 The Board’s approach to engagement 91 Board performance 94 Board Committee information 96 Our Board Committee reports 97 Section 172 statement 108 Directors’ report 109 GSK Annual Report 2020 77 Chairman’s Governance statement In last year’s Governance statement, I explained that our primary Education and focus on Science objective for 2020 was to ensure there was clarity between the Given the critical importance of strengthening the pipeline, Board and management on GSK’s execution of strategy and its the Board has benefitted from devoting a higher proportion of operational priorities. We have aligned our long-term priorities its time in understanding the science behind our strategy and of Innovation, Performance and Trust powered by culture testing its application. It is important that the Board has a and agreed on the metrics to measure delivery against them. working understanding of the key strategic themes upon The Board’s annual cycle of meetings ensures that all major which our R&D strategy is based. These themes have been components of our strategy are reviewed over the course complemented by Board R&D science thematic deep dives. of the year. Our focus was on the fundamentals of our strategy: human The COVID-19 pandemic impacted and dominated all our genetics, the immune system and AI and ML, as well as to lives for the majority of 2020.
  • Governance and Remuneration 2014

    Governance and Remuneration 2014

    Governance & remuneration reportStrategic In this section Our Board 72 Our Corporate Executive Team 76 Chairman’s letter 78 Corporate governance framework 79 Board report to shareholders Oversight and stewardship in 2014 and future actions 80 remuneration & Governance Leadership and effectiveness 82 Committee reports Audit & Risk 86 Nominations 92 Corporate Responsibility 94 Remuneration report Chairman’s annual statement 96 Annual report on remuneration 97 2014 Remuneration policy report 119 Financial statements Financial Investor information Investor GSK Annual Report 2014 71 Our Board Strategic reportStrategic Diversity Experience International experience Composition Tenure (Non-Executives) % % % % Scientific 19 Global 75 Executive 19 Up to 3 years 39 % % % % Finance 31 USA 100 Non-Executive 81 3-6 years 15 % % % % Industry 50 Europe 94 Male 69 7-9 years 23 % % % EMAP 63 Female 31 Over 9 years 23 Sir Christopher Gent 66 Skills and experience Chairman Sir Christopher has many years of experience of leading global businesses and a track record of delivering outstanding performance Governance & remuneration & Governance Nationality in highly competitive industries. He was appointed Managing Director British of Vodafone plc in 1985 and then became its Chief Executive Officer Appointment date in 1997 until his retirement in 2003. Sir Christopher was also a 1 June 2004 and as Chairman Non-Executive Director of Ferrari SpA and a member of the British on 1 January 2005 Airways International Business Advisory Board. Committee membership External appointments Corporate Responsibility Sir Christopher is a Senior Adviser at Bain & Co. Committee Chairman, Nominations, Remuneration and Finance Sir Philip Hampton 61 Skills and experience Chairman Designate Prior to joining GSK, Sir Philip chaired major FTSE 100 companies including J Sainsbury plc.
  • MORPHIC HOLDING, INC. (Name of Issuer)

    MORPHIC HOLDING, INC. (Name of Issuer)

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) MORPHIC HOLDING, INC. (Name of Issuer) Common Stock, Par Value $0.0001 (Title of Class of Securities) 61775R 10 5 (CUSIP Number) Victoria A. Whyte GlaxoSmithKline plc 980 Great West Road Brentford, Middlesex TW8 9GS England Telephone: +44 (0)208 047 5000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) June 23, 2020 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐ Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
  • Annual Report of Proxy Voting Record Date

    Annual Report of Proxy Voting Record Date

    ANNUAL REPORT OF PROXY VOTING RECORD DATE OF REPORTING PERIOD: JULY 1, 2018 - JUNE 30, 2019 FUND: VANGUARD FTSE 100 UCITS ETF --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ISSUER: 3i Group Plc TICKER: III CUSIP: G88473148 MEETING DATE: 6/27/2019 FOR/AGAINST PROPOSAL: PROPOSED BY VOTED? VOTE CAST MGMT PROPOSAL #1: ACCEPT FINANCIAL STATEMENTS AND ISSUER YES FOR FOR STATUTORY REPORTS PROPOSAL #2: APPROVE REMUNERATION REPORT ISSUER YES FOR FOR PROPOSAL #3: APPROVE FINAL DIVIDEND ISSUER YES FOR FOR PROPOSAL #4: RE-ELECT JONATHAN ASQUITH AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #5: RE-ELECT CAROLINE BANSZKY AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #6: RE-ELECT SIMON BORROWS AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #7: RE-ELECT STEPHEN DAINTITH AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #8: RE-ELECT PETER GROSCH AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #9: RE-ELECT DAVID HUTCHISON AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #10: ELECT COLINE MCCONVILLE AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #11: RE-ELECT SIMON THOMPSON AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #12: RE-ELECT JULIA WILSON AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #13: REAPPOINT ERNST & YOUNG LLP AS AUDITORS ISSUER YES FOR FOR PROPOSAL #14: AUTHORISE BOARD ACTING THROUGH THE ISSUER YES FOR FOR AUDIT AND COMPLIANCE COMMITTEE TO FIX REMUNERATION OF AUDITORS PROPOSAL #15: AUTHORISE EU POLITICAL DONATIONS AND ISSUER YES FOR FOR EXPENDITURE PROPOSAL #16: AUTHORISE ISSUE
  • Gulfstream – Nonstop

    Gulfstream – Nonstop

    VOLUME 02 EDITION 2012 LUXE KICKS DESTINATION DUBAI FLY-BY-WIRE Sole Men Bespoke Italian shoes hit their stride By LIz GroSSMAn fter starring in a span of criti- Bontoni’s standard of craftsman- cally acclaimed films in the ’90s, ship ranks among the highest of any Daniel Day-Lewis disappeared bespoke Italian shoemaker. from the public eye. From 1999 to 2000, the eccentric, reclusive actor wasn’t preparing for a role; rather he was holed up as a dili- gent apprentice at a cobbler’s studio in Florence, Italy. His mentor? Master shoemaker Stefano Bemer, who passed away in July. Bemer handcrafted bespoke men’s shoes with waxed, handwoven flat laces; used calf or exotic leathers like crocodile, stingray, sharkskin or ostrich; and sent the finished work of art to his clients in a monogrammed wooden box. Throughout his life, the shoe- maker taught other celebrities like Andy Garcia and designer Gianfranco Ferré the art of measuring, cutting, stitching and constructing bespoke men’s shoes. But it was Day-Lewis who showed up at 8 a.m. daily for almost a year, and reportedly became disturbed when a stitch wasn’t exactly right. Day-Lewis, also an avid woodworker, may very well have an eye for craftsman- ship, but chances are Bemer helped fuel his passion for shoemaking. A legend in the shoes are still turned out of a tiny bottega in aspect of the shoe, from the height of bespoke world of Italian shoes, Bemer’s the town of Montegranaro, located in the the heel, to the design of the medallion, devotion and talent will be sorely missed, Le Marche region of east-central Italy.
  • An American Identity: Shoemaker's Labels in Colonial

    An American Identity: Shoemaker's Labels in Colonial

    AN AMERICAN IDENTITY: SHOEMAKER'S LABELS IN COLONIAL. REVOLUTIONARY AND FEDERAL AMERICA, 1760-1820 by Meaghan M. Reddick A Thesis Submitted to the Graduate Faculty of George Mason University in Partial Fulfillment of The Requirements for the Degree of Master of Arts History of Decorative Arts Committee: ~~~~ ___ ---lCL~~-~·~~·~.."""""-_'~7'l""'------Program Director .:~'..:.:l,':'.~~., .:~»::::~ ..,. Department Chairperson ~s:, Ywyh Dean, College of Humanities and Social Sciences Date: A OR-I I ~O I d-O I f Spring Semester 2014 , George Mason University Fairfax, VA An American Identity: Shoemaker’s Labels in Colonial, Revolutionary and Federal America, 1760-1820 A Thesis submitted in partial fulfillment of the requirements for the degree of Master of Arts at George Mason University by Meaghan M. Reddick Bachelor of Arts Hollins University, 2008 Director: Mary D. Doering, Adjunct Professor Department of History of Decorative Arts Spring Semester 2014 George Mason University Fairfax, VA Copyright: 2014 Meaghan M. Reddick All Rights Reserved ii DEDICATION To my husband, Danny, Who has never been in doubt about who I was, and where I was going. Thank you for giving me the world, every single day. Daniel Patrick and Ashby Thomas, my sons, who I hope will be proud of me when they look back on my life. My parents, Paul and Suzanne Devlin, my sister Bronwyn, Who have watched me grow patiently, allowed me to thrive and supported my dreams from the beginning. To Ebenezer Breed, To whom I hope my research did him justice as a patriot And advocate of the American shoe industry. To future shoe historians, I hope this research inspires you to look “beyond the label”.
  • Drug Plan Formulary 2Nd Ed (June 2012).Pdf

    Drug Plan Formulary 2Nd Ed (June 2012).Pdf

    Disclaimer: This guide is offered as an easy reference to the prescription drugs that are supported by the National Prescription Drug Plan. It is by no means intended or to be construed as a directive to physicians to prescribe any of the drugs listed in the Formulary, nor does the National Insurance Board, by making available this guide, assume any responsibility for any treatment regimen or prescription drugs physicians prescribe for their patients with reference to the Formulary. The treatment and prescription process remains the sole purview of physicians in consultation with their patients. NATIONAL PRESCRIPTION DRUG PLAN FORMULARY TABLE OF CONTENTS Foreword ................................................................................. 3 Patient Registration Eligibility.................................................. 8 Completing Registration Forms .................................................. 9 Prescription Processing .......................................................... 10 Key Abbreviations .................................................................. 13 Arthritis .............................................................................. 16 Asthma ............................................................................... 45 Benign Prostatic Hypertrophy (BPH) ..................................... 58 Breast Cancer .................................................................. 63 Diabetes ............................................................................. 69 Epilepsy .............................................................................
  • Cusip No. G8807B106 13 D/A2 Page 2 of 7

    Cusip No. G8807B106 13 D/A2 Page 2 of 7

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* THERAVANCE BIOPHARMA, INC. (Name of Issuer) Ordinary Shares (Title of Class of Securities) G8807B106 (CUSIP Number) Victoria A. Whyte GlaxoSmithKline plc 980 Great West Road Brentford, Middlesex TW8 9GS England Telephone: +44 (0)208 047 5000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) December 31, 2016 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐ Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
  • What Makes a Great Chief Executive? What Makes a Great Chief Executive? Material Consists of 80% Recycled Certification

    What Makes a Great Chief Executive? What Makes a Great Chief Executive? Material Consists of 80% Recycled Certification

    Material consists of 80% recycled post-consumer fibre; 10% TCF (totally chlorine free); 10% ECF (elemental chlorine free). FSC certification. NAPM recycled certification. Paper mill accredited with ISO 9001 and ISO 14001 status. All responsibilities to the local environment and manufacturing processes are strictly monitored. The Whitehead Mann Leadership Debate Leadership Mann Whitehead The What makes a great Chief Executive? Chief great a makes What THE WHITEHEAD MANN LEADERSHIP DEBATE LEADERSHIP MANN WHITEHEAD THE What makes a great Chief Executive? Chief agreat What makes Contact Carol Leonard All rights reserved. No part of this publication Whitehead Mann is one of the world’s best-known leadership consultancies may be reproduced, stored in a retrieval system, working with clients to create value through people. As an independent, Whitehead Mann or transmitted in any form or by any means, international partnership, we work as a single team to deliver deep sector Ryder Court electronic, mechanical, photocopying, recording and functional expertise. We are authorities in the areas of leadership; CEO 14 Ryder Street or otherwise, without the express permission concerns; CEO characteristics and career issues at Board and CEO level. London SW1Y 6QB of the copyright owner. Our long track record is built on our contacts, judgement, the quality of our t +44 (0) 207 024 9000 © The Whitehead Mann Partnership LLP board placements and our ability to identify the CEOs of tomorrow. Over 90 f +44 (0) 207 024 9001 of Europe’s top 200 companies and most of the FTSE 100 companies and e [email protected] Fortune 500 organisations have retained Whitehead Mann.
  • This Document Was Submitted in Support of An

    This Document Was Submitted in Support of An

    This document was submitted in support of an entry into the SCA Arts & Sciences competition known as “Ice Dragon” held April 14, 2018, in the Barony of the Rhydderich Hael (see http://www.ice­dragon.info/) . Many thanks to the individuals who judged this and all entries and provided feedback on them, as well as to those who organized and staffed the event. Further related material can be found on the web at http://shoesbyrobert.com/shoeswp/projects/a­pair­of­black­and­whites/ Copyright 2018 by Ken Stuart (Lord Robert of Ferness), except for the illustrations, which are cited from their original sources. The author may be contacted at k [email protected] with questions, comments, etc. Decorated Viking Age Turnshoes for Court Categories Leatherworking and Accessories: non­textile. (Also, Special 5­in­1 for Leatherworking, Accessories: non­textile, Heraldic Display, Needlework: embroidery, Fiber Arts: weaving) THL Elska á Fjárfelli requested that I make her a pair of shoes to wear at court tonight, for her special appearance on the occasion of her Laural­induction ceremony. Specifically, she asked them to be replicas of exemplars known from 10th­century Dorstadt. Thus, this entry, made to fit her and for her, most personally. Although this pair of shoes is not the first I’ve made, it does incorporate a number of “firsts” for me, including first leather embroidery, first finger weaving, and first card weaving; also my first use of fur on shoes. (As for the weaving, this is not only the first time I’ve applied it as decoration on shoes, it’s the first time I’ve ever attempted finger­ and card­weaving projects of any size whatsoever.) Some surviving medieval shoes sport embroidery and many more have traces of its use inferred from needlework patterns in the leather.
  • Corporate Governance

    Corporate Governance

    65 GSK Annual Report 2018 Strategic report Governance and remuneration Financial statements Investor information Corporate Governance In this section Chairman’s Governance statement 66 Our Board 68 Our Corporate Executive Team 71 Leadership and effectiveness 72 Nominations Committee report 77 Accountability 79 Audit & Risk Committee report 79 Relations with stakeholders 89 Engagement activities 89 Science Committee report 91 Corporate Responsibility Committee report 92 Directors’ report 94 66 GSK Annual Report 2018 Chairman’s Governance statement “Our purpose and values have always been a source of great pride for the Board and our employees. It is a powerful force in attracting and retaining talented people who, as individuals, want to be part of a company that contributes meaningfully to society.” Dear Shareholder The Reforms came into effect on 1 January 2019 and seek to drive a I am pleased to present our Corporate Governance report for 2018. number of changes to companies’ underlying corporate governance processes. As a result, the Board has reviewed our existing practices Our governance structure operates from the Board across the Group to identify where they are in line with the Reforms and implemented and we believe it underpins our ability to deliver our strategy and enhancements where appropriate. We will report against the create long-term value and benefit for our shareholders and Reforms in next year’s Annual Report to allow time to embed these stakeholders. new practices in our corporate governance framework and to monitor I can confirm that throughout 2018 the company complied with their operation and effectiveness. the requirements of the Financial Reporting Council’s (FRC) UK However, I wish to highlight in this Report some of the more Corporate Governance Code (current Code) except that Dr Vivienne significant implementation steps which may be of interest to our Cox was unable to attend the company’s 2018 AGM.